Lantheus Holdings, Inc. $LNTH Shares Acquired by Pacer Advisors Inc.

Pacer Advisors Inc. boosted its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 21.3% in the third quarter, HoldingsChannel.com reports. The firm owned 422,180 shares of the medical equipment provider’s stock after purchasing an additional 74,272 shares during the quarter. Pacer Advisors Inc.’s holdings in Lantheus were worth $21,654,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Elevation Point Wealth Partners LLC acquired a new position in shares of Lantheus during the 2nd quarter valued at $26,000. Osterweis Capital Management Inc. bought a new position in Lantheus during the second quarter valued at about $36,000. Quarry LP grew its holdings in Lantheus by 2,350.0% during the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 470 shares during the period. EverSource Wealth Advisors LLC raised its position in Lantheus by 190.2% in the second quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock worth $87,000 after acquiring an additional 698 shares in the last quarter. Finally, EMC Capital Management acquired a new stake in Lantheus in the 2nd quarter valued at about $93,000. 99.06% of the stock is owned by institutional investors.

Lantheus Trading Up 0.0%

Lantheus stock opened at $66.71 on Friday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.49 and a current ratio of 2.67. The firm has a market capitalization of $4.42 billion, a price-to-earnings ratio of 28.03 and a beta of -0.10. The company has a 50 day moving average price of $58.96 and a 200 day moving average price of $62.23.

Lantheus (NASDAQ:LNTH) last released its earnings results on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share (EPS) for the quarter. The company had revenue of $92.51 million during the quarter. Lantheus had a return on equity of 30.88% and a net margin of 10.99%. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on LNTH. TD Cowen lowered their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. B. Riley reduced their target price on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a report on Tuesday, September 16th. Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a report on Saturday, October 25th. Mizuho raised their price objective on Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, Truist Financial lifted their target price on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Five investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.